Register Now
Contact Us
Subscribe

2025 Canadian Hematology Today Symposium on B-Cell Malignancies

April 11–13, 2025
Register Now
Conference Objectives
Join us from April 11 to 13 at The Westin Harbour Castle Hotel in Toronto for the 2025 Symposium on B-Cell Malignancies.
During the conference, we will:
  • Provide current and high-quality information on the latest developments in the management of B-cell malignancies
  • Create collegial learning opportunities that enable clinicians to incorporate real-world learnings into their practice
  • Foster discussions that allow for the sharing of knowledge and experience among delegates and representatives
  • Respond to emerging professional needs for specific and in-depth information on newly available and forthcoming therapies for B-cell malignancies in the Canadian market
We encourage you to secure your spot by registering for the conference using the link below. Registration will close on January 1, 2025, or once capacity is reached. A limited number of travel grants are available for this annual meeting so we strongly encourage you to register early to secure attendance at the conference.
 
Register Now
Scientific Steering Committee
Dr. Diego Villa
MD, MPH, FRCPC
BC Cancer Agency
University of British Columbia

Dr. Julie Stakiw

MD, FRCPC

Saskatchewan Cancer Agency

University of Saskatchewan

Dr. Isabelle Fleury

MD, FRCPC

Maisonneuve-Rosemont Hospital

University of Montreal

Faculty & Moderators

Dr. Ash Alizadeh

Biography

Dr. Peter Anglin

Biography

Dr. Suheil Albert Atallah-Yunes

Biography

Dr. Versha Banerji

Biography

Dr. Michael Crump

Biography

Dr. Kelly Davison

Biography

Dr. Alessandra Ferrajoli

Biography

Dr. Ronan Foley

Biography

Prof. Chris Fox

Biography

Dr. Ann S. LaCasce

Biography

Dr. Guido Lancman

Biography

Dr. Arleigh McCurdy

Biography

Dr. Tycel Phillip

Biography

Dr. Anca Prica

Biography

Dr. Robert Puckrin

Biography

Dr. Gita Thanarajasingam

Biography
Conference Agenda

Time

Topic

Speaker

Moderator

7:45 – 8:20 am

Sponsored Breakfast Symposium,
GSK Canada

TBD

8:20 – 8:25 am

Welcome & Opening Remarks

Diego Villa, MD & Isabelle Fleury, MD

8:25 – 8:55 am

Keynote Presentation: Assessment of Adverse Events in Hematologic Malignancies

Gita Thanarajasingam, MD

Diego Villa, MD

8:55 – 9:25 am

Session: Geriatric assessment of CAR T-cell therapy

Anca Prica, MD

Ronan Foley, MD

9:25 – 9:55 am

Session: BiTEs in DLBCL: Are we ready for 1st/2nd line use?

Tycel Philips, MD

Robert Puckrin, MD

9:55 – 10:10 am

Health Break

10:10 – 10:40 am

Session: Management of Primary CNS lymphoma

Prof. Chris Fox

Michael Crump, MD

10:40 – 11:10 am

Session: Liquid biopsy in DLBCL – Where are we in 2025?

Ash Alizadeh, MD

Michael Crump, MD

11:10 – 11:40 am

Session: Management of post-transplant lymphoprolifeactive disorder in 2025

Suheil Albert Atallah-Yunes, MD

TBD

11:40 – 12:45 pm

Buffet Lunch

12:45 – 1:15 pm

Sponsored Lunch Symposium,
Eli Lilly Canada

TBD

1:15 – 1:45 pm

Session: What’s the new standard for first line HL?

Ann LaCasce, MD

Isabelle Fleury, MD

1:45 – 2:15 pm

Session: Guidelines for CLL survivorship

Alessandra Ferrajoli, MD

Versha Banerji, MD

2:15 – 2:45 pm

Session: Management of CLL patients with 17p del (frontline + relapse)

TBD

Versha Banerji, MD

2:45 – 3:00 pm

Health Break

3:00 – 3:30 pm

Session: Management of POD24 in FL & MZL

Kelly Davison, MD

Isabelle Fleury, MD

3:30 – 4:00 pm

Session: The Canadian myeloma algorithm in 2025 – An Update

Arleigh McCurdy, MD

Peter Anglin, MD

4:00 – 4:30 pm

Session: Sequencing for CAR T-cell and bi-specifics for MM in 2025

Guido Lancman, MD

Peter Anglin, MD

4:30 – 4:35 pm

Closing Remarks & Adjournment

Diego Villa, MD & Isabelle Fleury, MD

Our Sponsors
Founding Sponsors
Platinum Sponsor
Gold Sponsor
Silver Sponsors
beigene
Bronze Sponsors

Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.

The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians and researchers across Canada. It features peer-reviewed articles that present robust clinical perspectives and practical insights into disease management.

Subscribe Now →
Subscribe To Canadian Hematology Today
About Catalytic Health

Founded in 2009, Catalytic Health is one of Canada’s largest medical education agencies and reaches over 50,000 Canadian clinicians a year with its educational programs, services and platforms. Catalytic Health is also the largest independent medical publisher in Canada, one of the largest scientific conference providers, and a leader in innovative events and services for the Life Sciences industry. Learn more about Catalytic Health.

Other Events
Contact Us
Linkedin Envelope Link

© 2025 All Rights Reserved.

Time

Session

Speaker

Moderator

CloseMenu

Following his clinical subspecialty, Hematology and Medical Oncology training at Stanford, he completed his postdoctoral studies with Ron Levy and Irv Weissman. During this time, he worked on molecular outcome prediction in DLBCL, developing a statistical framework for the identification of small numbers of genes for robust risk stratification and prognosis. Working with Irv Weissman, he identified CD47 expression as an adverse prognostic factor in non-Hodgkin lymphomas, and a therapeutic target of novel monoclonal antibodies that synergize to eradicate tumors.

The Alizadeh Lab studies genomic biomarkers of tumors, whether detected through biopsy of primary tissues, or non-invasively through monitoring blood using circulating tumor DNA (ctDNA). His group developed Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) as a novel method for ctDNA detection, and developed a novel cell deconvolution framework (CIBERSORT). His group applies such genomic tools for early detection, diagnosis, and monitoring of diverse tumors. In this effort, his group builds and employs tools from functional genomics, computational biology, molecular genetics, and mouse models.

CloseMenu
  • Dr. Peter Anglin’s clinical focus remains in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. He has also developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients. He continues to serve in an advisory capacity to a number of pharmaceutical and health-related organizations. He remains the medical director of CarePath, a cancer navigation and support service supporting Cancer Care Ontario and Ontario cancer patients.
CloseMenu
  • Dr. Atallah-Yunes, is a hematologist-oncologist with a specialized focus on lymphoid malignancies. He obtained his medical degree from the University of Jordan and completed his internal medicine residency at the University of Massachusetts Chan Medical School, followed by a fellowship in hematology-oncology at Indiana University. He then completed an advanced fellowship in lymphoma at the Mayo Clinic in Rochester, Minnesota. Currently, Dr. Atallah-Yunes is enrolled in an advanced fellowship program in cell therapy at the Mayo Clinic concentrating on cell therapy in lymphoma. His research interests focus on rare lymphomas and the use of novel targeted agents and cell therapy to improve outcomes, particularly in complex conditions such as post-transplant lymphoproliferative disorders.
CloseMenu

Dr. Versha Banerji obtained her MD and residency training in internal medicine and hematology at the University of Manitoba. She then completed a post-doctoral fellowship in translational research at the Harvard Cancer Centre/Dana-Farber Cancer Institute and the Broad Institute of MIT. She is a senior scientist at the CancerCare Manitoba Research Institute, Associate Professor at the University of Manitoba, and a clinician-scientist at CancerCare Manitoba. She co-leads the CLL clinic and is involved in several clinical trials and population-based treatment studies. As co-chair of the CLL research program she manages a multi-disciplinary research team in clinical, fundamental and translational research. Her own laboratory is evaluating mitochondrial bioenergetics and function as a measure of cancer cell metabolism.

CloseMenu

Dr Michael Crump is a Hematologist in the Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre, and Professor of Medicine at the University of Toronto. He was the co-chair of the Hematology Site Group of the CCTG for many years and the co-chair of the Lymphoma working group. His research interests include the development of new therapies for lymphomas including bispecific antibodies and chimeric antigen receptor (CAR) T cells and the application of autologous stem cell transplantation.

CloseMenu

Dr. Kelly Davison is an assistant professor in the Department of Medicine at McGill University, and a hematologist at the Royal Victoria Hospital, McGill University Health Centre. She initially obtained her medical degree from McGill University after completing a PhD in the field of molecular oncology. Thereafter, she pursued residency training in Internal Medicine, and subspecialty training in Hematology, at McGill University, followed by a two-year fellowship in lymphoma and autologous stem cell transplantation at Princess Margaret Cancer Centre.

Dr. Davison joined the MUHC’s division of Hematology in 2013, where she continues to have clinical and research interests that centre on the management of lymphoma. She is a member of the MUHC’s stem cell transplant and immune effector cell therapy group and is the clinical CAR-T lead for lymphoma. She is an active member of the Canadian Cancer Trials Group’s lymphoma subcommittee and was the Canadian chair on the recently completed HDC.1 trial evaluating a novel treatment strategy for advanced stage Hodgkin lymphoma.

CloseMenu
  • Dr. Alessandra Ferrajoli is a professor of Leukemia at MD Anderson. She also serves as Deputy Chair of the Department of Leukemia and the associate medical director of MD Anderson’s Leukemia Center, one of the world’s most recognized treatment centers for leukemia and blood disorders. As an academic hematologist and oncologist, Dr. Ferrajoli’s main areas of interest include the treatment and biology of chronic lymphocytic leukemia and its variants, as well as the treatment of elderly patients with acute and chronic leukemia. She earned her medical degree at the University of Perugia, in Italy, and completed internal medicine residencies at both the University of Perugia and The University of Texas Medical School. She also completed a research clinical immunology and biological therapy fellowship as well as a clinical hematology/oncology fellowship at MD Anderson. Among her many accolades, she has received MD Anderson’s Faculty Achievement Award in Patient Care, and she is a four-time recipient of the institution’s Teacher of the Year Award for her mentorship in the Leukemia Fellowship Program.
CloseMenu
  • Ronan Foley, MD, FRCPC, is a clinical hematologist with an active practice in malignant hematology at the Juravinski Cancer Centre and Director of the Stem Cell Laboratory and Dr. Foley is a Professor of Pathology and Molecular Medicine at McMaster University, President of CBMTG, a Director of the Clinical Trials Network. His other activities include board membership on OCREB and panel chair for the CIHR CBT panel. Dr. Foley’s current research focus is the development of therapeutic cell-based autologous vaccines. He has held grants with CANVAC, OICR, CIHR, OCRN, and CBCRA.
CloseMenu

Prof Chris Fox (MBChB FRCP FRCPath PhD) is Professor of Haematology at the School of Medicine, University of Nottingham and Honorary Consultant Haematologist at Nottingham University Hospitals NHS Trust.

His research interests focus on the aggressive lymphomas and he currently Chairs the UK’s aggressive lymphoma study group. Prof Fox is the Medical Director for the UK TAP (therapy- accelerated programme) blood cancer trials delivery network. He is Chief Investigator and steering committee member for several early and late phase national and international clinical trials. He has co-authored and peer-reviewed manuscripts in high-impact journals including NEJM, The Lancet, Lancet Oncology, Lancet Haematology, Journal of Clinical Oncology, Blood, BMJ.

CloseMenu

Dr. Ann S. LaCasce earned her medical degree from Tufts University School of Medicine. She completed training in internal medicine at Brigham and Women’s Hospital in Boston, where she later served as a Chief Medical Resident. After her fellowship in medical oncology at Dana-Farber/Partners Cancer Care, she pursued formal training in clinical investigation, earning a Master in Medical Science from Harvard/MIT Division of Health Sciences and Technology. Since 2003, she has been a member of the Lymphoma Program at Dana-Farber where she performs clinical research. She has a longstanding interest in medical education, and is the Program Director of the Dana-Farber/Mass General Brigham Fellowship in hematology/oncology. In addition, she co-directs the Center for Adolescent and young Adult Oncology at Dana-Farber. She is an Associate Professor of Medicine at Harvard Medical School. She is Chair of the Lymphoma Research Foundation Scientific Advisory Board and serves on the ABIM Medical Oncology Board, the National Comprehensive Cancer Network’s Lymphoma Guideline Panel, and the Alliance Lymphoma Committee.

CloseMenu

Guido Lancman is a clinical associate at the Princess Margaret Cancer Centre and adjunct Assistant Professor in the Department of Medicine at the University of Toronto. Prior to coming to Toronto, he obtained his M.D. at the Icahn School of Medicine at Mount Sinai in New York, and his M.Sc. in Clinical Trials with distinction at University College London in the UK. He completed his Internship and Residency in Internal Medicine, as well as his Fellowship in Hematology and Medical Oncology at Mount Sinai. Dr Lancman was involved in research throughout his training, receiving the Mount Sinai Summer Research Scholars Award in medical school, the SOHO Young Investigator Travel Award in residency, and obtaining funding for two investigator-initiated studies during his fellowship. His research has focused on optimizing the efficacy and safety of novel therapies in multiple myeloma, with a particular interest in immunotherapies. He is involved in the development of multiple myeloma clinical trials through Princess Margaret and through the Canadian Myeloma Research Group.

CloseMenu

Dr. Arleigh Robertson McCurdy, MHA, MD, FRCPC, is an Associate Professor in the Faculty of Medicine at the University of Ottawa, Lead of the Multiple Myeloma Program at The Ottawa Hospital, and a Clinician Investigator at The Ottawa Hospital Research Institute. Her clinical research is focused on multiple myeloma and related disorders. She is a member of the Canadian Cancer Trials Group Myeloma Committee, the International Myeloma Working Group, and she is a director on the Canadian Myeloma Research Group Board of Directors.

CloseMenu

Dr. Tycel J. Phillips, M.D. is a Hematologist-Oncologist and Associate Professor of Medicine at City of Hope Comprehensive Cancer Center in Duarte, CA. Dr. Phillips earned his medical degree from Rush University, followed by a residency in internal medicine at the John H. Stroger Jr. Hospital of Cook County in Chicago. He completed his fellowship training in oncology/hematology at University Hospitals in Cleveland. Before joining City of Hope, he was a Clinical Associate Professor at the University of Michigan, where he was appointed the Maria Reinhardt DeCesare Research Professor of Blood Cancers and Bone Marrow Transplantation. Cancer care is a personal mission for Dr. Phillips. Leading clinical trials into new targeted therapies is a vital part of his work. He has published over 40 peer-reviewed studies and attracted dozens of research grants. Dr. Phillips currently serves as an executive committee member on the Lymphoma Research Foundation’s Mantle Cell Lymphoma Consortium, guiding the MCLC by identifying gaps in research and patient care for the MCL patient population.

CloseMenu

Dr. Anca Prica is a staff hematologist at Princess Margaret Cancer Centre, and associate professor in the division of hematology at University of Toronto, appointed in 2014. She is currently the site lead of the lymphoma and myeloma program at Princess Margaret Cancer Centre. She did her initial medical training in Toronto, and her clinical training in Internal Medicine and Hematology in the University of Toronto Program.  She then did a 2 year fellowship in Malignant Hematology at the Sunnybrook Health Sciences Centre and a Masters in Health Research Methodology at McMaster University, with research interests in quality of life and economic evaluations. Her clinical work focuses in both lymphoproliferative and plasma cell disorders, as well as autologous stem cell transplantation and CAR-T therapy. Her research interests focus on health services research, particularly economic evaluations and decision analyses for oncologic questions, examining resource use and cost of care, as well as toxicity of chemotherapies, and their effects on quality of life and caregiver burden.

CloseMenu
  • Dr. Robert Puckrin is a hematologist at the Arthur Child Cancer Centre and the University of Calgary in Calgary, Canada. His main interests are in lymphoma, cellular therapies, bispecific antibodies, clinical trials, and real-world data.
CloseMenu

Dr. Gita Thanarajasingam is an Associate Professor of Medicine and consultant in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. She is a graduate of Yale University and Mayo Clinic Alix School of Medicine and completed her residency at the Brigham and Women’s Hospital at Harvard Medical School. After Hematology and Oncology Fellowship and Advanced Lymphoma Fellowship at Mayo Clinic, she joined the faculty of the Mayo Clinic Rochester Lymphoma disease-oriented group.

Her clinical practice as an oncologist is focused on Hodgkin and non-Hodgkin lymphoma, and she performs health outcomes research in lymphoma and other cancers. As a clinical investigator, her work focuses on improving the evaluation of adverse events (AEs) of treatment and measuring their impact on treatment tolerability cancer patients. She developed the Toxicity over Time (ToxT), a longitudinal patient-focused approach to AE evaluation. She is active in the implementation of patient-reported outcomes (PRO) to better understand treatment toxicity and tolerability. 

She serves of as vice co-chair of the Alliance for Clinical Trials in Oncology Health Outcomes Committee and is the recipient of K and U01 grants from the U.S. National Institutes of Health. She leads the ongoing international multi-stakeholder Lancet Haematology Commission, “Beyond maximum grade: modernizing the assessment and reporting of adverse events in hematological malignancies.” She is an international advisory board member of the Lancet Haematology and an ad-hoc member of the U.S. Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) with expertise in toxicity assessment. Her research program overall endeavors to improve the accuracy and patient-centeredness of AE evaluation and better understand cancer treatment tolerability from the patient’s perspective.